A network model of genomic hormone interactions underlying dementia and its translational validation through serendipitous off-target effect

BackgroundWhile the majority of studies have focused on the association between sex hormones and dementia, emerging evidence supports the role of other hormone signals in increasing dementia risk. However, due to the lack of an integrated view on mechanistic interactions of hormone signaling pathways associated with dementia, molecular mechanisms through which hormones contribute to the increased risk of dementia has remained unclear and capacity of translating hormone signals to potential therapeutic and diagnostic applications in relation to dementia has been undervalued.MethodsUsing an integrative knowledge- and data-driven approach, a global hormone interaction network in the context of dementia was constructed, which was further filtered down to a model of convergent hormone signaling pathways. This model was evaluated for its biological and clinical relevance through pathway recovery test, evidence-based analysis, and biomarker-guided analysis. Translational validation of the model was performed using the proposed novel mechanism discovery approach based on ‘serendipitous off-target effects’.ResultsOur results reveal the existence of a well-connected hormone interaction network underlying dementia. Seven hormone signaling pathways converge at the core of the hormone interaction network, which are shown to be mechanistically linked to the risk of dementia. Amongst these pathways, estrogen signaling pathway takes the major part in the model and insulin signaling pathway is analyzed for its association to learning and memory functions. Validation of the model through serendipitous off-target effects suggests that hormone signaling pathways substantially contribute to the pathogenesis of dementia.ConclusionsThe integrated network model of hormone interactions underlying dementia may serve as an initial translational platform for identifying potential therapeutic targets and candidate biomarkers for dementia-spectrum disorders such as Alzheimer’s disease.

[1]  J. Buxbaum,et al.  Pharmacological concentrations of the HMG-CoA reductase inhibitor lovastatin decrease the formation of the Alzheimer beta-amyloid peptide in vitro and in patients. , 2002, Frontiers in bioscience : a journal and virtual library.

[2]  S. L. Gray,et al.  Actions and interactions of the IGF system in Alzheimer's disease: review and hypotheses. , 2000, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[3]  JoAnn E. Manson,et al.  Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. , 2004 .

[4]  William A Banks,et al.  Brain meets body: the blood-brain barrier as an endocrine interface. , 2012, Endocrinology.

[5]  C. Nemeroff,et al.  CSF corticotropin-releasing factor (CRF) in Alzheimer's disease: Its relationship to severity of dementia and monoamine metabolites , 1989, Biological Psychiatry.

[6]  George Perry,et al.  Leptin: a novel therapeutic strategy for Alzheimer's disease. , 2009, Journal of Alzheimer's disease : JAD.

[7]  Jiapei Dai,et al.  Glucocorticoid hormone (cortisol) affects axonal transport in human cortex neurons but shows resistance in Alzheimer's disease , 2004, British journal of pharmacology.

[8]  A. Miyashita,et al.  A Map of Alzheimer's Disease–Signaling Pathways: A Hope for Drug Target Discovery , 2013, Clinical pharmacology and therapeutics.

[9]  Eric M Reiman,et al.  Altered neuronal gene expression in brain regions differentially affected by Alzheimer's disease: a reference data set. , 2008, Physiological genomics.

[10]  Mathias Jucker,et al.  The benefits and limitations of animal models for translational research in neurodegenerative diseases , 2010, Nature Medicine.

[11]  Martin Hofmann-Apitius,et al.  Mining biomarker information in biomedical literature , 2012, BMC Medical Informatics and Decision Making.

[12]  E. D. Haan,et al.  Insulin-like growth factor-I and cognitive function in healthy older men. , 1999, The Journal of clinical endocrinology and metabolism.

[13]  Mathieu Bastian,et al.  Gephi: An Open Source Software for Exploring and Manipulating Networks , 2009, ICWSM.

[14]  Sanjay Asthana,et al.  Insulin Metabolism in Alzheimer’s Disease Differs According to Apolipoprotein E Genotype and Gender , 1999, Neuroendocrinology.

[15]  Dick J. Veltman,et al.  Effects of Growth Hormone Substitution Therapy on Cognitive Functioning in Growth Hormone Deficient Patients: A Functional MRI Study , 2006, Neuroendocrinology.

[16]  Jian-Zhi Wang,et al.  Role of melatonin in Alzheimer-like neurodegeneration , 2006, Acta Pharmacologica Sinica.

[17]  D F Swaab,et al.  Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer's disease, and apolipoprotein E-epsilon4/4 genotype. , 1999, The Journal of clinical endocrinology and metabolism.

[18]  Ines Liebich,et al.  EndoNet: an information resource about endocrine networks , 2005, Nucleic Acids Res..

[19]  J. Dartigues,et al.  Characteristics of hormone therapy, cognitive function, and dementia , 2009, Neurology.

[20]  A. Barabasi,et al.  Network biology: understanding the cell's functional organization , 2004, Nature Reviews Genetics.

[21]  Xiaoping Guan,et al.  Estrogen-Induced Activation of Mitogen-Activated Protein Kinase in Cerebral Cortical Explants: Convergence of Estrogen and Neurotrophin Signaling Pathways , 1999, The Journal of Neuroscience.

[22]  S. Minoshima,et al.  Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. , 2011, Archives of neurology.

[23]  Christian Hölscher,et al.  Neuronal mechanisms of memory formation : concepts of long-term potentiation and beyond , 2000 .

[24]  J. Cauley,et al.  Diabetes, glucose control, and 9-year cognitive decline among older adults without dementia. , 2012, Archives of neurology.

[25]  John Boyle,et al.  Cytoscape: a community-based framework for network modeling. , 2009, Methods in molecular biology.

[26]  Kaj Blennow,et al.  Cerebrospinal fluid τ and β-amyloid(1-42) in dementia disorders , 2001, Mechanisms of Ageing and Development.

[27]  P. Zandi,et al.  Hormone Replacement Therapy and Incidence of Alzheimer Disease in Older Women , 2011 .

[28]  T. Teyler.  Long-term potentiation and memory. , 1987, International journal of neurology.

[29]  Yaakov Stern,et al.  Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease , 1996, The Lancet.

[30]  D. Alkon,et al.  Insulin and the insulin receptor in experimental models of learning and memory. , 2004, European journal of pharmacology.

[31]  Ben Lehner,et al.  Tissue specificity and the human protein interaction network , 2009, Molecular systems biology.

[32]  V. Henderson,et al.  Estrogen replacement therapy and risk of Alzheimer disease. , 1996, Archives of internal medicine.

[33]  J. Lamerdin,et al.  Identifying off-target effects and hidden phenotypes of drugs in human cells , 2006, Nature chemical biology.

[34]  Jennifer D. Davis,et al.  Thyroid hormone levels in the prefrontal cortex of post-mortem brains of Alzheimer's disease patients. , 2008, Current aging science.

[35]  A Hofman,et al.  Diabetes mellitus and the risk of dementia , 1999, Neurology.

[36]  Allan Kuchinsky,et al.  GLay: community structure analysis of biological networks , 2010, Bioinform..

[37]  I. Izquierdo,et al.  Learning-associated activation of nuclear MAPK, CREB and Elk-1, along with Fos production, in the rat hippocampus after a one-trial avoidance learning: abolition by NMDA receptor blockade. , 2000, Brain research. Molecular brain research.

[38]  Siegfried Benkner,et al.  @neuLink: A Service-oriented Application for Biomedical Knowledge Discovery , 2008, HealthGrid.

[39]  F Savoldi,et al.  Cholinergic modulation of growth hormone-releasing hormone effects on growth hormone secretion in dementia. , 1990, Neuropsychobiology.

[40]  Alexandra M. Dumitrescu,et al.  Thyroid hormone mediated changes in gene expression can be initiated by cytosolic action of the thyroid hormone receptor β through the phosphatidylinositol 3-kinase pathway , 2006, Nuclear receptor signaling.

[41]  Rosemary O’Connor,et al.  Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling , 2010, Neurobiology of Aging.

[42]  Sheng He,et al.  fMRI revealed neural substrate for reversible working memory dysfunction in subclinical hypothyroidism. , 2006, Brain : a journal of neurology.

[43]  G. Moore,et al.  Prefrontal cortex as the site of estrogen's effect on cognition , 2001, Psychoneuroendocrinology.

[44]  Mark A. Reger,et al.  Insulin effects on CSF norepinephrine and cognition in Alzheimer's disease , 2006, Neurobiology of Aging.

[45]  G. Frühbeck,et al.  Intracellular signalling pathways activated by leptin. , 2006, The Biochemical journal.

[46]  M. Dubocovich,et al.  Molecular pharmacology, regulation and function of mammalian melatonin receptors. , 2003, Frontiers in bioscience : a journal and virtual library.

[47]  Daniel Hanisch,et al.  ProMiner: rule-based protein and gene entity recognition , 2005, BMC Bioinformatics.

[48]  Sudha Seshadri,et al.  Association of plasma leptin levels with incident Alzheimer disease and MRI measures of brain aging. , 2009, JAMA.

[49]  J. Wands,et al.  Alzheimer's Disease is Type 3 Diabetes—Evidence Reviewed , 2008, Journal of diabetes science and technology.

[50]  Yasuo Hishikawa,et al.  Melatonin secretion rhythm disorders in patients with senile dementia of Alzheimer’s type with disturbed sleep–waking , 1999, Biological Psychiatry.

[51]  K. Becker,et al.  The Genetic Association Database , 2004, Nature Genetics.

[52]  L. Fratiglioni,et al.  Medical history and the risk of Alzheimer's disease: a collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group. , 1991, International journal of epidemiology.

[53]  Sarah A. Stern,et al.  A critical role for IGF-II in memory consolidation and enhancement , 2011, Nature.

[54]  Baldo Oliva,et al.  Integration and Prediction of PPI Using Multiple Resources from Public Databases , 2008 .

[55]  W. Kamphorst,et al.  Metabolic Alterations in the Hypothalamus and Basal Forebrain in Vascular Dementia , 2004, Journal of neuropathology and experimental neurology.

[56]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[57]  D. Jolley,et al.  Cost benefits of a medically supervised day treatment program for patients with Alzheimer's disease and other forms of dementia , 1989 .

[58]  Chih-Cheng Hsu,et al.  Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin. , 2011, Journal of Alzheimer's disease : JAD.

[59]  Robert S. Schwartz,et al.  Growth hormone releasing hormone improves the cognition of healthy older adults , 2006, Neurobiology of Aging.

[60]  M. Gianelli,et al.  Relationship between Cognitive Function, Growth Hormone and Insulin-Like Growth Factor I Plasma Levels in Aged Subjects , 1998, Neuropsychobiology.

[61]  S. Rapoport,et al.  Cerebrospinal fluid concentrations of corticotropin‐releasing hormone (CRH) and corticotropin (ACTH) are reduced in patients with Alzheimer's disease , 1987, Neurology.

[62]  Brenda L Plassman,et al.  Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. , 2002, JAMA.

[63]  Helga Thorvaldsdóttir,et al.  Molecular signatures database (MSigDB) 3.0 , 2011, Bioinform..

[64]  Steven T. DeKosky,et al.  Association between dementia and elevated TSH: A community-based study , 1996, Biological Psychiatry.

[65]  Anne-Catherine Bachoud-Lévi,et al.  Neuroendocrine Disturbances in Huntington's Disease , 2009, PloS one.

[66]  J. Ávila,et al.  Estradiol inhibits GSK3 and regulates interaction of estrogen receptors, GSK3, and beta-catenin in the hippocampus , 2004, Molecular and Cellular Neuroscience.

[67]  David J Brooks,et al.  Imaging amyloid in Parkinson's disease dementia and dementia with Lewy bodies with positron emission tomography , 2009, Movement disorders : official journal of the Movement Disorder Society.

[68]  G. Schellenberg,et al.  Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease , 1998, Neurology.

[69]  R. Raffa,et al.  Diabetes mellitus and Alzheimer's disease: shared pathology and treatment? , 2011, British journal of clinical pharmacology.

[70]  Nancy L. Pedersen,et al.  O1-05-08: Mid- and late-life diabetes in relation to the risk of dementia: A population-based twin study , 2008, Alzheimer's & Dementia.

[71]  Dapeng Liang,et al.  Concerted Perturbation Observed in a Hub Network in Alzheimer’s Disease , 2012, PloS one.

[72]  Ai Ling Fu,et al.  Thyroid hormone prevents cognitive deficit in a mouse model of Alzheimer's disease , 2010, Neuropharmacology.

[73]  Sanjay Asthana,et al.  Insulin dose–response effects on memory and plasma amyloid precursor protein in Alzheimer’s disease: interactions with apolipoprotein E genotype , 2003, Psychoneuroendocrinology.

[74]  G. V. Van Hoesen,et al.  The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. , 1991, Cerebral cortex.

[75]  Hideyuki Okano,et al.  Regulation of tau RNA Maturation by Thyroid Hormone Is Mediated by the Neural RNA-Binding Protein Musashi-1 , 2002, Molecular and Cellular Neuroscience.

[76]  C P Maurizi,et al.  Loss of intraventricular fluid melatonin can explain the neuropathology of Alzheimer's disease. , 1997, Medical hypotheses.

[77]  R. Gibbs,et al.  Estrogen therapy and cognition: a review of the cholinergic hypothesis. , 2010, Endocrine reviews.

[78]  C. Ross,et al.  Protein aggregation and neurodegenerative disease , 2004, Nature Medicine.

[79]  David Eisenberg,et al.  In Brief , 2009, Nature Reviews Neuroscience.

[80]  D. Price,et al.  Abnormalities in Corticotropin‐releasing Hormone (CRH) in Alzheimer's Disease and Other Human Disorders a , 1987, Annals of the New York Academy of Sciences.

[81]  F. Pasquier,et al.  Risk profiles for mild cognitive impairment and progression to dementia are gender specific , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[82]  Federico Licastro,et al.  Endogenous sex hormones as risk factors for dementia in elderly men and women. , 2007, The journals of gerontology. Series A, Biological sciences and medical sciences.

[83]  Eric Altermann,et al.  PathwayVoyager: pathway mapping using the Kyoto Encyclopedia of Genes and Genomes (KEGG) database , 2005, BMC Genomics.

[84]  Eva L. Feldman,et al.  How does diabetes accelerate Alzheimer disease pathology? , 2010, Nature Reviews Neurology.

[85]  Kuo-Fen Lee,et al.  Corticotropin-Releasing Factor Receptors Differentially Regulate Stress-Induced Tau Phosphorylation , 2007, The Journal of Neuroscience.

[86]  S. Kanba,et al.  Glucose tolerance status and risk of dementia in the community , 2011, Neurology.

[87]  D. Alkon,et al.  Role of insulin and insulin receptor in learning and memory , 2001, Molecular and Cellular Endocrinology.

[88]  Robert B Wallace,et al.  Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. , 2003, JAMA.

[89]  Koji Abe,et al.  Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease , 2003, Journal of neurochemistry.